Related Experiment Videos
Montelukast in general pediatric practices.
1Department of Pediatrics, Allergy and Immunology Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. ngamphaiboon_j@yahoo.com
Summary
Montelukast effectively treats childhood allergic diseases like asthma and allergic rhinitis by blocking inflammatory pathways. It offers a favorable safety profile, improving quality of life for affected children.
Area of Science:
- Pediatric Allergy and Immunology
- Pharmacology of Anti-inflammatory Agents
Background:
- Allergic diseases such as asthma, allergic rhinitis, and atopic dermatitis are prevalent in children.
- Understanding disease pathogenesis has led to targeted anti-inflammatory therapies like Montelukast.
Purpose of the Study:
- To review the efficacy and safety of Montelukast in pediatric allergic diseases.
- To evaluate Montelukast's role in asthma and allergic rhinitis management.
Main Methods:
- Systematic review of studies on Montelukast's therapeutic effects.
- Analysis of clinical trial data comparing Montelukast with placebo and inhaled corticosteroids (ICS).
Main Results:
- Montelukast demonstrates efficacy in treating asthma, allergic rhinitis, and related symptoms.
- It is effective as monotherapy for mild persistent asthma and as an adjunct to ICS for moderate-to-severe asthma.
- Montelukast shows a safety profile comparable to placebo and superior to ICS.
Conclusions:
- Montelukast is a valuable therapeutic option for managing pediatric allergic diseases, including asthma and allergic rhinitis.
- The drug can improve patient quality of life, particularly in those with comorbid conditions.